News | Stents | October 22, 2015

LEADERS FREE Trial Supports Polymer-free Drug-coated Stent for High Bleeding Risk Patients

BioFreedom DCS with one-month dual antiplatelet therapy regimen offers treatment option for those normally excluded from stent and drug trials

October 22, 2015 — Results from the LEADERS FREE trial found that a polymer-free drug-coated stent (DCS) was superior to a bare-metal stent (BMS) in high-bleeding-risk patients treated with one month of dual antiplatelet therapy (DAPT). It was the first randomized clinical trial dedicated to this particular patient population.  

Findings from the study were presented last week at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). Study results were also published in the New England Journal of Medicine.

Patients at high risk of bleeding during percutaneous coronary intervention (PCI) are mostly excluded from device and antiplatelet therapy trials. Current recommendations for high-risk patients are one month of DAPT after BMS implantation and a “shortened” DAPT regimen after DES. LEADERS FREE examined the use of one month of DAPT for both types of stents, specifically studying the BioFreedom DCS from Biosensors International, which uses stent surface modification (rather than a drug delivery polymer) to elute lipophilic drug biolimus A9.

The prospective double-blind randomized study enrolled 2,466 patients with high bleeding risk during PCI. Patients were randomized 1:1 to receive a DCS (n=1,221) or BMS (n=1,211). Superiority for the primary safety endpoint (composite of cardiac death, myocardial infarction and definite/probable stent thrombosis at one year post-procedure) was met with 112 (9.4 percent) for DCS and 154 (12.9 percent) for BMS. [Risk difference -3.6 percent (95 percent CI -6.1 percent to -1 percent), HR 0.71, (95 percent CI = 0.56 – 0.91), p < 0.0001 for non-inferiority and p = 0.005 for superiority].

The results for the primary efficacy endpoint of clinically-driven TLR at one year were 5.1 percent for DCS versus 9.8 percent for BMS. [Risk difference -4.8 percent (95 percent CI = -6.9 percent to -2.6 percent), HR 0.50, (95 percent CI = 0.37 – 0.69), p<0.001 for superiority].

“Patients who have a high risk of bleeding during PCI are often excluded from stent and drug trials but constitute a rapidly growing proportion of PCI candidates and they suffer high event rates,” said lead investigator Philip M. Urban, M.D., director of interventional cardiology at La Tour Hospital in Geneva, Switzerland. “The LEADERS FREE trial clearly showed that a drug-eluting stent combined with a one-month-only DAPT course was both significantly safer and more effective than a bare-metal stent in this subset of patients.”

The LEADERS FREE trial was funded by Biosensors Europe Ltd. Urban is a paid consultant for Biosensors Europe Ltd.

For more information: www.tctconference.com

Related Content

Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the ex
cardiologist Ted Feldman, M.D., at TCT 2017. #TCT2018 #TCT #TCT18 TCT Late breaking trials, studies.
Feature | TCT | September 21, 2018
October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clini
Interventional cardiology, cath lab technology, TCT, transcatheter cardiovascular therapeutics. #TCT #TCT18 #TCT2018
Feature | TCT | September 14, 2018 | Dave Fornell, Editor
The volume of information attendees receive at the annual...
Videos | TCT | November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT | November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Key Interventional Cardiology and structural heart Technologies to Prepare for TCT 2017.
Feature | TCT | October 26, 2017 | Dave Fornell
Here is an aggregation of DAIC content for all major cardiovascular technology news and advances this past year. These...
Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Videos | TCT | November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Videos | TCT | November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) ann
Overlay Init